Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Boston Scientific

BSX

HIGHLY FAVORABLE

May 22, 2026

Research Conclusion

BUY at ~$52.68. Boston Scientific is the world's fastest-growing major medical device company (+19.9% FY2025 revenue), trading at 15.5x FY2026E adj EPS — half-priced vs. growth peers SYK (25x) and EW (24x). The -52% drawdown from peak was driven by FARAPULSE deceleration (+73% → +24%) and Watchman softness, both of which appear to be base-effect normalization and capacity-driven rather than structural share loss. PWFV $77 (+46%); base case $83 (+57%); bear case $53 (0% — bounded). Re-rate to growth peer mid-range alone delivers +60%+.

Company Overview & Moat Assessment

Boston Scientific is a global medical device manufacturer with $20.1B revenue (FY2025, +19.9% YoY). Two segments: MedSurg ($6.8B, +6.7% organic) and Cardiology ($13.3B, +25%+). FARAPULSE established BSX as the leader in pulsed field ablation for AF (70% US PFA share as of late 2025). CEO Mike Mahoney has executed consistent acquisitions: Axonics (Nov 2024), LimFlow DVA, Silk Road. Adj EBITDA margin 28% expanding to 32% target. Recent ~$78B market cap reflects -52% drawdown from peak.

▲ Bull Case

  • ◆FARAPULSE share stabilizes 60-65%; total PFA market doubles by FY2028. Absolute FARAPULSE revenue grows +25%/yr; competitive entries (MDT, JNJ) don't displace BSX leadership; international PFA expansion (EU 30% vs US 60% penetration) becomes next growth chapter.
  • ◆Watchman re-accelerates H2 2026. Hospital capacity constraints ease; volume growth returns to +15-20%; new indications (HRS post-stroke AF) expand TAM.
  • ◆ACURATE neo2 US approval + acquisition pipeline. TAVI approval FY2027 → +$500M revenue; tuck-in M&A adds $500M-1B revenue/yr at accretive prices.

▼ Bear Case

  • ◆FARAPULSE share falls below 55%; MDT becomes EP lab default. Competitive entries take share; BSX PFA leadership erodes; organic growth slows to +5-6%; multiple compresses to 14-16x.
  • ◆Watchman declines -2-5% volume; structural saturation. LAAC procedure penetration plateaus; volumes stall; narrative shifts from growth to mature device.
  • ◆Goodwill impairment >$2B on Axonics/LimFlow. Writedowns signal acquisition strategy mispriced; capital allocation grade declines.
Primary Debate on Wall Street

“The primary debate is whether FARAPULSE deceleration represents share loss (bear) or market normalization (bull). Bulls cite PFA market doubling FY2026-2028; bears cite competitive entries plus Watchman softness as signs of structural decline.”

Top Catalysts
  • ◆Q2 FY2026 earnings (Jul/Aug 2026): EP growth >20%; Watchman re-accelerating signals inflection
  • ◆FARAPULSE share data (quarterly): 65%+ US share = bull thesis; <55% = bear thesis confirmation
  • ◆Watchman volume inflection (Q2/Q3 2026): Growth re-acceleration to +20% eases capacity concerns
  • ◆Abbott VOLT FDA clearance (2026-2027): 3rd PFA competitor; tests competitive defensibility
  • ◆ACURATE neo2 US data (FY2026-2027): TAVI US launch potential +$500M revenue
Top Risks
  • ◆FARAPULSE share <55% (MEDIUM prob, HIGH impact): Bear case materializes; share loss thesis confirmed
  • ◆Watchman structural decline (LOW-MEDIUM prob, MEDIUM impact): Cardiology growth slows; saturation thesis
  • ◆Goodwill impairment >$2B (LOW-MEDIUM prob, MEDIUM impact): Acquisition story damaged; capital allocation questioned
  • ◆Acquisition overpay (MEDIUM prob, LOW-MEDIUM impact): Chronic risk given M&A-focused strategy
  • ◆Macro/medtech sector pullback (MEDIUM prob, MEDIUM impact): Beta exposure; multiple compression risk

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/BSX/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.